Supplemental Material

Supplement 1 (additional table). Propensity score model for transradial access.

| Variable                        | Multivariable | p     |
|---------------------------------|---------------|-------|
| Age                             | 1.01 (1.00-1.03) | 0.07  |
| Male                            | 1.11 (0.80-1.54) | 0.52  |
| Hypertension                    | 1.29 (0.91-1.81) | 0.15  |
| Hypercholesterolemia            | 1.16 (0.83-1.63) | 0.40  |
| Diabetes                        | 0.99 (0.75-1.31) | 0.96  |
| Family History                  | 0.85 (0.64-1.13) | 0.25  |
| Current Smoker                  | 0.78 (0.49-1.25) | 0.30  |
| Prior Stroke                    | 0.99 (0.68-1.42) | 0.94  |
| Prior MI                        | 0.86 (0.65-1.12) | 0.26  |
| Prior PCI                       | 0.86 (0.65-1.14) | 0.30  |
| Peripheral Artery Disease       | 0.89 (0.65-1.22) | 0.47  |
| Chronic Kidney Disease          | 0.84 (0.61-1.15) | 0.27  |
| CABG Anatomy Known              | 1.17 (0.54-2.56) | 0.69  |
| LIMA Used                       | 1.05 (0.72-1.51) | 0.81  |
| RIMA Used                       | 1.48 (0.95-2.30) | 0.08  |
| SVG Used                        | 0.87 (0.56-1.34) | 0.52  |
| CA/PCI <48 h Post-CABG          | 0.30 (0.15-0.62) | < 0.01|
| STEMI                           | 0.63 (0.38-1.04) | 0.07  |
| PCI Performed                   | 1.63 (0.59-4.49) | 0.35  |
| Sheath Size (6 French)          | 0.41 (0.19-0.88) | 0.022 |
| Native Vessel Treated           | 0.66 (0.20-2.14) | 0.48  |
| Graft Vessel Treated            | 0.44 (0.13-1.48) | 0.19  |
Supplement 1 (additional table). Propensity score model for transradial access (continuation).

| Variable                  | Multivariable | p   |
|---------------------------|---------------|-----|
| Multiple Vessels Treated  | 0.52 (0.14-1.91) | 0.33 |
| Lesion Class B2C          | 0.80 (0.46-1.38) | 0.43 |
| Implanted Stents          | 0.79 (0.57-1.09) | 0.16 |
| Total Stent Length        | 1.01 (1.00-1.02) | 0.20 |
| Procedure Time            | 1.00 (1.00-1.01) | 0.34 |
| Fluoroscopy Time          | 1.01 (1.00-1.03) | 0.09 |
| Radiation Exposure        | 1.00 (1.00-1.00) | < 0.01 |
| Glycoprotein Inhibitor Used | 0.77 (0.39-1.52) | 0.45 |
| Thienopyridine Derivate Used | 1.75 (1.07-2.86) | 0.025 |

Values are odds ratios (ORs) with 95% confidence intervals (CIs).

CA = coronary angiography; CABG = coronary artery bypass graft; LIMA = left internal mammary artery; MI = myocardial infarction; PCI = percutaneous coronary intervention; RIMA = right internal mammary artery; STEMI = ST-elevation myocardial infarction; SVG = saphenous vein graft.
Supplement 2 (additional figure). 1-year Kaplan-Meier curves for the composite primary efficacy endpoint (major adverse cardiovascular events) and each individual component.

|          | TFA |                   |      | TRA |                   |      |
|----------|-----|-------------------|------|-----|-------------------|------|
| Risk (n) | 615 | 516               | 498  | 469 | 450               | 405  |
| Events (n) | 62  | 87                | 105  | 37  | 52                | 66   |
| Cum. Incidence (%) | 10.1 | 14.1               | 17.1  | 7.0  | 11.1               | 14.1  |

**MACE**

- TFA
- TRA

**All-cause Mortality**

- TFA
- TRA

**Myocardial Infarction**

- TFA
- TRA

**Stroke**

- TFA
- TRA

**UTVR**

- TFA
- TRA
Survival plots (12 months) for transfemoral vs transradial access.

MACE = major adverse cardiovascular events; TFA = transfemoral access; TRA = transradial access; UTVR = urgent target vessel revascularization.